Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ITCI

Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis

Intra-Cellular Therapies logo

About Intra-Cellular Therapies Stock (NASDAQ:ITCI)

Advanced Chart

Key Stats

Today's Range
$131.87
$131.87
50-Day Range
$131.87
$131.87
52-Week Range
$70.90
$131.98
Volume
N/A
Average Volume
1.55 million shs
Market Capitalization
$14.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$109.70
Consensus Rating
Hold

Company Overview

Intra-Cellular Therapies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

ITCI MarketRank™: 

Intra-Cellular Therapies scored higher than 18% of companies evaluated by MarketBeat, and ranked 865th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Intra-Cellular Therapies has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 10 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Intra-Cellular Therapies has received no research coverage in the past 90 days.

  • Read more about Intra-Cellular Therapies' stock forecast and price target.
  • Earnings Growth

    Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.64) to $0.19 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Intra-Cellular Therapies is -151.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Intra-Cellular Therapies is -151.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Intra-Cellular Therapies has a P/B Ratio of 21.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for ITCI.
  • Dividend Yield

    Intra-Cellular Therapies does not currently pay a dividend.

  • Dividend Growth

    Intra-Cellular Therapies does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ITCI.
  • News Sentiment

    Intra-Cellular Therapies has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Intra-Cellular Therapies this week, compared to 6 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Intra-Cellular Therapies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.60% of the stock of Intra-Cellular Therapies is held by insiders.

  • Percentage Held by Institutions

    92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Intra-Cellular Therapies' insider trading history.
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Headlines

ITCI Stock Analysis - Frequently Asked Questions

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its earnings results on Friday, February, 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.08. The biopharmaceutical company had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 9.93% and a negative net margin of 14.07%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Intra-Cellular Therapies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
2/21/2025
Today
7/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ITCI
CIK
1567514
Employees
560
Year Founded
N/A

Price Target and Rating

High Price Target
$132.00
Low Price Target
$74.00
Potential Upside/Downside
-16.8%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$139.67 million
Net Margins
-14.07%
Pretax Margin
-13.87%
Return on Equity
-9.93%
Return on Assets
-8.38%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.66
Quick Ratio
7.51

Sales & Book Value

Annual Sales
$680.50 million
Price / Sales
20.64
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.15 per share
Price / Book
21.44

Miscellaneous

Outstanding Shares
106,522,000
Free Float
103,563,000
Market Cap
$14.05 billion
Optionable
Optionable
Beta
0.69

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:ITCI) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners